Rchr
J-GLOBAL ID：200901000509858649   Update date: Nov. 07, 2024

Nishikawa Kiyotaka

ニシカワ キヨタカ | Nishikawa Kiyotaka
Affiliation and department：
Doshisha University Faculty of Life and Medical Sciences Department of Medical Life Systems

About Doshisha University Faculty of Life and Medical Sciences Department of Medical Life Systems


Job title： Professor
Research field  (1)： Pharmaceuticals - health and biochemistry
Research theme for competitive and other funds  (18)：
  • 2021 - 2025 Establishment of a novel therapeutic strategy against influenza virus infection based on the regulation of cellular lipid metabolism.
  • 2021 - 2025 魚類細胞の細胞老化を司る分子機構の解明
  • 2021 - 2024 細胞内新生Sタンパクを標的とした新規COVID-19治療薬の開発
  • 2017 - 2021 Development of therapeutic agents against influenza that induce the formation of lamella body to inhibit the viral propagation.
  • 2018 - 2020 Functional analysis of inducible lamellar body as novel type of self-defense machinery against influenza A virus infection.
Show all
Papers (63)：
  • Watanabe-Takahashi M.*, Tanigawa T., Hamabata T., Nishikawa K.*. A tetravalen;peptide efficiently inhibits the intestinal;oxicity of heat-labile enterotoxin by targeting the receptor-binding region of the;B-subuni;pentamer. Biochem. Biophys. Res. Commun. 2024. 734. 150769
  • Watanabe-Takahashi M*, Kumoi K, Yamamoto H, Shimizu E, Motoyama J, Hamabata T, Nishikawa K*. Tailored multivalent peptide targeting the B-subunit pentamer of Cholera toxin inhibits its intestinal toxicity by inducing aberrant transport of the toxin in cells. Biochem. Biophys. Res. Commun. 2024. 716. 149991
  • Hama S., Watanabe-Takahashi M., Nishimura H., Omi J., Tamada M., Saitoh T., Maenaka K., Okuda Y., Ikegami A., Kitagawa A., et al. CaMKII-dependent non-canonical RIG-I pathway promotes influenza virus propagation in the acute-phase of infection. mBio. 2024. in press
  • Sato W, Watanabe-Takahashi M, Murata T, Utsunomiya-Tate N, Motoyama J, Anzai M, Ishihara S, Nishioka N, Uchiyama H, Togashi J, et al. A tailored tetravalent peptide displays dual functions to inhibit amyloid β production and aggregation. Commun. Biol. 2023. 6(1)383. 1. 383-383
  • Deguchi A*, Watanabe-Takahashi M, Mishima T, Omori T, Ohto U, Arashiki N, Nakamura F, Nishikawa K*, Maru Y*. Novel multivalent S100A8 inhibitory peptides attenuate tumor progression and metastasis by inhibiting the TLR4-dependent pathway. Cancer Gene Therapy. 2023. Mar. 17;1-12
ｍore...
MISC (16)：
  • 佐藤和佳, 舟本 聡, 西川喜代孝. Amyloid betaの産生と凝集を共に阻害するペプチド性化合物の開発. ファルマシア. 2024. 60. 8. 764-768
  • 近江純平, 西川喜代孝. 誘導性アンフィソームはインフルエンザウイルス感染防御に働く. 生化学. 2021. 93. 234-238
  • 小川 莉奈, 長尾 耕治郎, 原 雄二, 田村 朋則, 浜地 格, 井上 飛鳥, 青木 淳賢, 高橋 美帆, 西川 喜代孝, 梅田 真郷. 4価型人工ペプチドを用いたホスファチジン酸結合プローブの開発. 脂質生化学研究. 2015. 57. 170-173
  • 小川莉奈, 宮崎俊秀, 長尾耕治郎, 原雄二, 佐々木善浩, 秋吉一成, 稲葉岳彦, 小林俊秀, 高橋美帆, 西川喜代孝, et al. ホスファチジン酸結合性を有する4価型人工ペプチドの開発. 日本生化学会大会(Web). 2014. 87th. 2T09A-10(2P-071) (WEB ONLY)-10]
  • 中津 大貴, 加納 ふみ, 田口 由起, 菅原 太一, 西園 貴志, 西川 喜代孝, 小田 裕香子, 古瀬 幹夫, 村田 昌之. JNK依存的なangulin-1/LSRのリン酸化は、上皮細胞シートに形成される三細胞接着点への、angulin-1/LSR及びtricellulinの保持に必須である. 日本細胞生物学会大会講演要旨集. 2014. 66回. 141-141
ｍore...
Patents (27)：
  • Abeta産生抑制ペプチドおよびこれを含有する医薬組成物、飲食品
  • S100A8-Inhibiting peptide and therapeutic drug for disease which containing same
  • S100A8-Inhibiting peptide and therapeutic drug for disease which containing same
  • LT阻害4価ペプチドおよびETEC感染症治療薬
  • EML4-ALK阻害ペプチドおよびこれを含む肺がん治療薬
ｍore...
Books (2)：
  • デブリン生化学原書7版-臨床の理解のために(Textbook of Biochemistry with Clinical Correlations, 7th Edition)
    丸善出版 2012
  • 図説薬理学のポイント("Pretty done quick; Pharmacology, by Johnson, G. E., Brian C. Decker, Inc., 1988")
    医学書院 1991
Lectures and oral presentations  (9)：
  • COVID-19, Influenza related topics.
    (DOSHISHA WEEK 2020/Webinar, COVOD-19 Research: Challenges and Achievements for the Society 2021)
  • Strategic development of peptide-based therapeutic agents against bacterial and viral infections
    (The 16th Awaji International Forum on Infection and Immunity 2017)
  • Peptide-based Stx-neutralizers of treatment of STEC infections
    (Seminar Series Fall 2015, Pathology and Laboratory Medicine 2015)
  • Peptide-based Stx-neutralizers of treatment of STEC infections
    (International Symposium “New trends of anti-infection strategy” on The 86th Annual Meeting of Japanese Society For Microbiology 2013)
  • Peptide-based neutralizers of Shiga toxin
    (International Union of Microbiological Societies 2011 Congress (IUMS2011) 2011)
ｍore...
Education (3)：
  • - 1989 The University of Tokyo
  • - 1986 The University of Tokyo
  • - 1984 The University of Tokyo Faculty of Pharmaceutical Sciences Department of Pharmacy
Professional career (2)：
  • 薬学博士 (東京大学)
  • 薬学修士 (東京大学)
Work history (5)：
  • 2008/04 - 現在 Doshisha University Faculty of Life and Medical Sciences, Department of Medical Life Systems
  • 2007/04 - 2008/03 - 同志社大学生命医科学部設置準備室 教授
  • 1998 - 2007 国立国際医療センター研究所臨床薬理研究部室長
  • 1995 - 1998 Harvard Medical School/Beth Israel Deaconess Medical Center, Division of Signal Transduction, Visiting Assistant Professor
  • 1989 - 1997 Keio University School of Medicine, Department of Pharmacology
Awards (2)：
  • 2013 - バイオビジネスアワードJAPAN彩都賞
  • 2012 - The prize for the Best Poster on Prevention, Control and Treatment: Animal and Human at the 8th International Symposium on Shiga toxin (Verocytotoxin) Producing Escherichia coli Infections
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM